[BREAKOUT ALERT!] NEW NASDAQ Pharma Breakout Stock with (317% Upside Potential)

New NASDAQ Breakout Alert For 11/20 Trading Session MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) Brand New Analyst Report Pegs a $16.50 Price Target ["Representing 371% Upside Gain From Current Price"]( Developing The Next Generation FDA Approved Novel Synthetic T∙H∙C Analog Hi “FDR” Member, This is Michael Reece with “FinancialDrivenResearch” delivering you your new breakout alert for Monday trading session 11/20 MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). “FDR” Initiates Coverage of MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) current price is $3.50/share. Zacks Small-Cap Research just released a game-changing research report predicting a 12- month price target at a staggering $16.50/share! Analyst Price Forecast Suggests 371% Upside MIRA Has a Potential 371% Upside From Current Price >> [See The Full Report Here Now]( << MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is a pre-clinical-stage pharmaceutical development company focused on the development of MIRA1a, a novel synthetic T∙H∙C analog. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with plant extr∙acts. MIRA1a is classified as an unscheduled dr∙ug by the U.S. Dr∙ug Enfo∙rcement Administration (D∙E∙A). MIRA1a is a compound that has shown in preclinical testing indications of having the benefits of T∙H∙C without the negative side effects—potentially aiding milli∙ons of patients. The company’s earnings report showed good ca∙sh balances. MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Earnings Don't Miss Out on 371% Upside Gain [See The Full Report Here Now]( MIRA reported 3Q earnings of -$0.26 per share as it continues to test and research its potential groundbreaking therapy. Most importantly, the company reported ca∙sh of $5.9 Mln, which is vitally important to a company at this stage and even more so due to the tight credit markets facing smaller companies. In response to these problems with traditional M∙M∙J, MIRA is developing a compound that offers the benefits while minimizing the potential negative side effects. That might sound too good to be true, but they are encouraged by the initial test results we’ve seen and impressed by the leadership and their passion for finding a solution to a problem plaguing a vast number of Americans. Overall, technical indicators are signaling a "Bullish STR∙ONG B∙U∙Y Rating" based on Investing.com technical analysis. MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is a First Mover To Market! MIRA1Aa, as it known, is being developed as the first prescription dr∙ug to target the receptors known as CB1 and CB2 for neuropathic pain, anxiety and cognitive enhancements without the impurities of M∙M∙J or its side effects such as those discussed above. Importantly, and for this to be a viable project, the company received great news on November 28, 2022, when the U.S. Dr∙ug Enfo∙rcement Agency (D∙E∙A) confirmed in writing that it conducted a scientific review of the chemical structure of MIRA1Aa in accordance with the definitions within the Con∙trolled Subs∙tances Act (CSA) and its implementing regulations and determined that MIRA1Aa is not a cont∙rolled sub∙stance or listed chemical. This means that MIRA1Aa can go through the traditional FDA approval process and be used by patients, if approved, without the logistical and financial complications of working with a Schedule 1 dr∙ug —a potential exciting and extremely beneficial breakthrough and a reason, in our view for investors to take a hard look at MIRA before it gets too far along in the process and more inve∙stors push up the price. Large/Unmet Target Markets MIRA Pharmaceuticals will have potential access to $90 Bln+ traditional neurological markets and $30 Bln c∙a∙n∙n∙ a∙b∙i∙s markets, representing a potential large revenue oppo∙rtunity Four Major Catalyst That Can Produce Triple-Digit Gain Potential For The Future - MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) received great news on November 28, 2022, when the U.S. Dr∙ug Enfor∙cement Agency (D∙E∙A) confirmed in writing that it conducted a scientific review of the chemical structure of MIRA1Aa in accordance with the definitions within the Cont∙rolled Subs∙tances Act (C∙S∙A) and its implementing regulations and determined that MIRA1Aa is not a cont∙rolled subs∙tance or listed chemical. - MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic T∙H∙C analog, announced its strategic partnership with MZ Group ("MZ"), a renowned international inve∙stor relat∙ions firm. This collaboration aims to enhance MIRA's visibility within the inves∙tment community and spotlight the potential of its d∙r∙u∙g can∙didate, MIRA1a, in treating anxiety, cognitive decline, and neuropathic pain. - MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) Continues to Pursue New Pain Relief. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it continues to test and research its potential groundbreaking therapy. Most importantly, the company reported ca∙sh of $5.9 Mln, which is vitally important to a company at this stage and even more so due to the tight credit markets facing smaller companies. - MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than P∙o∙t. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic analog named MIRA1a, explored the scientific and social drivers behind its development of MIRA1a today at the Derived D∙r∙u∙g Development Summit. The Company shared data and research that positions MIRA1a as a potential future alternative prescription medication with unique properties not found in as well as the potential for fewer side effects. MIRA Pharmaceuticals (NASDAQ: MIRA) Positions Itself With Incredible Leadership For Maximum Upside Potential Erez Aminov - Chief Executive Officer Erez Aminov is an experienced biotechnology consultant and investor. He is the CEO of Mira Pharmaceuticals (NASDAQ) and the founder of Locate Venture Corp. Additionally, Erez is a consultant for Telomir Pharmaceuticals, where he utilizes his vast knowledge and experience to drive growth and success. Erez’s accomplishments include identifying potential partnerships with major pharmaceutical and medical research centers and a deep understanding of early-stage startup growth and vertical integration. His vast industry network, which includes investment banks, PR and IR firms, and pharmaceutical contract development and manufacturing, has proven invaluable in driving startup success. Erez holds a B.A. in Accounting from Touro University in New York. He also served as a MyMD Pharmaceuticals (NASDAQ) senior consultant, providing valuable insights and guidance to support the company’s growth and success. Outside of work, Erez is a dedicated family man and avid traveler. He loves exploring new cultures and cuisines and believes in giving back to his community through various philanthropic efforts. Adam Kaplin, MD, PhD - Cofounder, President, Chief Scientific Officer Prior to joining MIRA Pharmaceuticals Dr. Kaplin served in a number of positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine, positions he has held at various times from 2002 to present. Since 2019, Dr. Kaplin as Adjunct Faculty at the George Mason University Department of Global and Community Health. Dr. Kaplin served as Co-Founder of numerous healthcare related startups, including, from 2018 to present, REWARD Pathways Inc., a company devoted to addiction treatment development focused on a combined eHealth and medicine approach to curing addiction, and from 2016 to present, Hollinger Kaplin Benjamin & Bond, an eHealth software development company. Dr. Kaplin’s research focuses on the investigation of the biological basis of immune mediated depression and cognitive impairment by using MS as the model. Dr. Kaplin has also been active for over a decade in the development and application of health information technology to mental health, combining this work with providing neuropsychiatric consultation and ongoing care of patients with MS spectrum disorders. Dr. Kaplin’s original research has been published over 40 times in several different publications, and he has authored or co-authored numerous review articles and textbooks. Dr. Kaplin received his B.S. in Biology from Yale University, graduating cum laude in 1988, and received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine in 1996. Michelle Yanez, MBA - Chief Financial Officer, Secretary, and Treasurer Michelle Yanez has been our Chief Financial Officer since April 2023, prior to which she served as our Corporate Controller since May 2022. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceuticals, and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit and finance committees. Ms. Yanez is part-time Corporate Controller at Telomir Pharmaceuticals, Inc., a privately held biotech company. From 2002 until its acquisition in 2022, Ms. Yanez held various positions in BioDelivery Sciences International, Inc. (NASDAQ), including the Director of Financial Reporting. In her role, she led financial offerings, managed due diligence for product acquisitions and financings and managed finance documents and filings for the tender offer, Ms. Yanez served as an independent director of Inhibitor Therapeutics, Inc., a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and certain non-cancerous proliferation disorders, since December 2022. Ms. Yanez is a member of the Institute of Management Accountants and a member of the S∙E∙C Professionals Group. Ms. Yanez received her MBA from Rutgers School of Business, Cum Laude. Christos Nicholoudis, Esq. - General Counsel Christos Nicholoudis joined the board of MIRA Pharmaceuticals in March 2023 as General Counsel for the company. A former public defender for the 12th Judicial Circuit for the State of Florida from 2019 to 2022, Mr. Nicholoudis developed invaluable courtroom and trial experience. He has represented clients struggling with substance abuse and his firsthand knowledge of the devastating effects of addiction provides Mira with a unique perspective and deep commitment to its mission. After his employment with the State, Mr. Nicholoudis started his own practice in February 2022, where he handles a wide range of legal matters including contract work, personal injury, real estate, wills trusts and estates and criminal law. Prior to his legal career, Mr. Nicholoudis worked in the hospitality industry where he owned and operated a restaurant in Bradenton Florida from 2012 to 2020 while simultaneously working to develop a 5-star hotel in Mykonos Greece with his family. Mr. Nicholoudis is a 2012 graduate of Cornell University’s School of Hotel Administration where he received a B.S. in hospitality and a 2017 graduate of Stetson College of Law where he received his J.D. He is admitted to the bar in New York, Florida, Texas, and Washington D.C. He speaks English, Greek, Russian and Hebrew and has exceptional public speaking skills. Aside from his scholastic achievements, Mr. Nicholoudis has been an athlete for his entire life. He graduated in 2008 from the IMG sports academy where he spent 10 years playing tennis, ice hockey and golf while also studying music and theater. He is a classically trained tenor who continues to volunteer in local community theater. (MIRA) Has a Potential 371% Upside From Current Price [See The Full Report Here Now]( Conclusion: Developing The Next Generation FDA Approved Novel Synthetic T∙H∙C Analog MIRA Pharmaceuticals is an early-stage life sciences company focused on the development and commercialization of MIRA1a, a synthetic analog of T∙H∙C. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and chronic pain without impurities or the negative side effects associated with plant extracts. Massive TAM, with a Dual-path MIRA Pharmaceuticals will have potential access to $90 Bln+ traditional neurological markets and $30 Bln c∙a∙n∙n∙a∙b∙i∙s markets, representing a potential large revenue oppo∙rtunity. MIRA currently trading at the $3.50 range has a incredible upside potential of $16.50/per share. That represents a clean 371% upside potential from here. I am urging all of our members to add MIRA Pharmaceuticals Inc. (MIRA) to the top of your watch list right now, and be ready Monday morning at the opening bell! To Your Trading Success, Michael Reece Editor, Financial Driven Research © 2023 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates has been compensated $12,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc∙laimer and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St Unit #83, 21211, Baltimore, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](